The U.S. Court of Appeals for the Federal Circuit upheld a Patent Trial and Appeal Board decision invalidating three 10x Genomics patents tied to single-cell nucleic-acid analysis. The ruling affirms a prior unpatentable-as-obvious finding in a dispute initiated by 10x against Parse Biosciences. Parse Biosciences, now part of Qiagen following its 2025 acquisition, had challenged the claims through administrative review, and the appeals court has now affirmed the invalidation. The decision does not affect a separate Delaware district court ruling invalidating another Scale Biosciences patent that had become part of 10x’s portfolio. For the single-cell genomics and diagnostics ecosystem, the outcome reinforces the importance of claim scope and obviousness standards for enabling methods, while shaping how companies evaluate freedom-to-operate strategies around core assay workflows.